Your Shopping Cart Is Empty
| ✷ Report Code: A03145 | Apr 2022 | Pages: 170 | ||
| Tables: 139 | Charts: 55 |
| |
The global smart insulin pens market share was valued at $94.76 million in 2020, and is projected to reach $298.87 million by 2030, growing at a CAGR of 12.1% from 2021 to 2030. Smart insulin pens are used for external insulin delivery, thus offering an easy to carry solution for diabetes management. This smart system calculates and tracks doses and provides helpful reminders, alerts, and reports. They can come in the form of an add-on to your current insulin pen or a reusable form, which uses prefilled cartridges instead of vials or disposable pens. A smart insulin pen can deliver accurate half-unit doses, help prevent skipped or missed doses, keep track of the time and amount of each dose, and remind when it is time for the next one, notify when the insulin has expired or exceeded its temperature range, so that patient can replace the cartridge, send diabetes data to health care team whenever needed and work with smart phone or smart watch and popular diabetes data tracking platforms.
The outbreak of COVID-19 has negative impact on smart insulin pens market. The cost of providing smart insulin pens may increase in the future due to increase in demand for more productive and cost-effective smart insulin pens, and increase in prevalence of diabetic patients globally. Amidst the COVID-19, there was implementation of lockdown everywhere and the patient faced difficulty to get smart insulin pens delivered on time due to of less production because the entire healthcare sector shifted toward treatment of COVID-19.
The demand for the insulin pens has increased considerably in the smart insulin pens market forecast owing to surge in incidence of diabetic patients coupled with their cost-effective nature as compared to insulin pumps. In addition, simple functioning and accuracy related to insulin dosing further stimulates its demand. However, there are certain disadvantages associated with the use of insulin pen such as two types of insulin cannot be mixed in an insulin pen, thus increasing the frequency of injections needed. This in turn impedes the smart insulin pens industry growth.
The upsurge in demand for smart insulin pens, rise in disposable incomes, and growth prospects in emerging economies of Asia-Pacific and LAMEA are expected to provide numerous opportunities for smart insulin pens market size growth during the forecast period. According to International Diabetes Federation, in 2021 approximately 537 million adults (20-79 years) are living with diabetes. The total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. About 3 in 4 adults with diabetes live in low and middle-income countries. Almost 1 in 2 (240 million) adults living with diabetes are undiagnosed. Diabetes caused 6.7 million deaths and more than 1.2 million children and adolescents (0-19 years) are living with type 1 diabetes whereas 1 in 6 live births (21 million) are affected by diabetes during pregnancy and around 541 million adults are at increased risk of developing type 2 diabetes.
Smart Insulin Pens Market Segmentation
The smart insulin pens market is segmented into By Type, Usability, End User and Region. By type, the market is categorized into first generation pens and second-generation pens. By usability, the market is categorized into pre-filled and reusable. By end user, the market is categorized into hospitals & clinics, ambulatory surgical centers, and home care settings.Regionwise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
Segment review
Depending on type, the first-generation pens segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to advancements in R&D activities in the healthcare sector and increase in diabetic population. The global first-generation smart insulin pens market was valued at $60.2 million in 2020, and is projected to reach $174.8 million by 2030, growing at a CAGR of 11.2% from 2021 to 2030. In addition, rise in awareness among people regarding the new and advanced methods for insulin delivery is also expected to boost the market growth. Second generation pens segment is expected to exhibit the fastest growth rate during the forecast period owing to increase in geriatric population and rise in the number of new product launches.
Depending on usability, the reusable pens segment dominated the market in 2020, reusable smart insulin pens are featured with memory and timing function that provides intelligent injection for patients and this trend is expected to continue during the forecast period. The global pre-filled smart insulin pens market was valued at $25.8 million in 2020, and is projected to reach $83.7 million by 2030, growing at a CAGR of 12.7% from 2021 to 2030. Prefilled segment is expected to exhibit the fastest growth rate during the forecast period owing to rise in awareness among people regarding the new and advanced methods for insulin delivery.
By end user, the hospital & clinics segment dominated the market in 2020. Generally, hospitals are well equipped with diabetes management products to accommodate to the various patients with type 1 and type 2 diabetes. Hospitals and clinics have skilled professionals and staff, which facilitates the delivery of insulin, enhance patient safety, increase patient comfort, and improve blood sugar. The global smart insulin pens market for hospital & clinics was valued at $35.5 million in 2020, and is projected to reach $107.3 million by 2030, growing at a CAGR of 11.7% from 2021 to 2030. Home care settings segment is expected to exhibit the fastest growth rate of CAGR 12.7% during the forecast period owing to increase in the number of home care settings that increase the demand for smart insulin pens.
By region, Europe garnered a major share in the smart insulin pens market in 2020, and is expected to continue to dominate during the forecast period, due to increase in incidence of diabetic patients, presence of key players, and development in R&D activities in healthcare sector in the region. Europe was the highest contributor to the global market with $38.9 million in 2020, and is projected to reach $119.2 million by 2030, registering a CAGR of 11.8%. Asia-Pacific smart insulin pens market is estimated to reach $52 million by 2030 growing at a CAGR of 11.4%. However, LAMEA is expected to register fastest growth rate with CAGR of 13.4% from 2021 to 2030, owing to surge in demand for smart insulin delivery products, increase in the number of advanced healthcare facilities.
The key players that operate in the smart insulin pens market include Berlin-Chemie, Bigfoot Biomedical, Digital Medics Pty Ltd., Eli Lilly and Company, Emperra GmbH, Jiangsu Deflu Medical Device Co. Ltd., Medtronic PLC, Novo Nordisk, Pendiq, and Sanofi.
Smart Insulin Pens Market Report Highlights
| Aspects | Details |
|---|---|
| By End User |
|
| By Type |
|
| By Usability |
|
| By Region |
|
| Key Market Players | Pendiq, Berlin-Chemie, Digital Medics Pty Ltd., Medtronic plc, Eli Lilly and Company, Novo Nordisk, Jiangsu Deflu Medical Device Co. Ltd., Sanofi, Emperra GmbH, Bigfoot Biomedical |
CHAPTER 1: Â INTRODUCTION
1.1.Report Description
1.2.Key Market Segments
1.3.Key Benefits
1.4.Research Methodology
1.4.1.Primary Research
1.4.2.Secondary Research
1.4.3.Analyst Tools and Models
CHAPTER 2: Â EXECUTIVE SUMMARY
2.1.CXO Perspective
CHAPTER 3: Â MARKET LANDSCAPE
3.1.Market Definition and Scope
3.2.Key Findings
3.2.1.Top Investment Pockets
3.2.2.Top Winning Strategies
3.3.Porter's Five Forces Analysis
3.3.1.Bargaining Power of Suppliers
3.3.2.Threat of New Entrants
3.3.3.Threat of Substitutes
3.3.4.Competitive Rivalry
3.3.5.Bargaining Power among Buyers
3.4.Market Share Analysis/Top Player Positioning
3.4.1. Market Share Analysis/Top Player Positioning 2020
3.5.Market Dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. Â COVID-19 Impact Analysis
CHAPTER 4: Â SMART INSULIN PENS MARKET, BY TYPE
4.1.Market Overview
4.1.1Market Size and Forecast, By Type
4.2. First Generation Pens
4.2.1.Key Market Trends, Growth Factors and Opportunities
4.2.2.Market Size and Forecast, By RegionÂ
4.2.3.Market Share Analysis, By Country
4.3. Second Generation Pens
4.3.1.Key Market Trends, Growth Factors and Opportunities
4.3.2.Market Size and Forecast, By RegionÂ
4.3.3.Market Share Analysis, By Country
4.3.4.Bluetooth-Enabled
4.3.4.1.Market Size and Forecast
4.3.5.Usability
4.3.5.1.Market Size and Forecast
CHAPTER 5: Â SMART INSULIN PENS MARKET, BY USABILITY
5.1.Market Overview
5.1.1Market Size and Forecast, By Usability
5.2. Prefilled
5.2.2.Market Size and Forecast, By RegionÂ
5.2.3.Market Share Analysis, By Country
5.3. Reusable
5.3.2.Market Size and Forecast, By RegionÂ
5.3.3.Market Share Analysis, By Country
CHAPTER 6: Â SMART INSULIN PENS MARKET, BY END USER
6.1.Market Overview
6.1.1Market Size and Forecast, By End User
6.2. Hospitals And Clinics
6.2.1.Market Size and Forecast, By RegionÂ
6.2.2.Market Share Analysis, By Country
6.3. Ambulatory Surgical Centers
6.3.1.Market Size and Forecast, By RegionÂ
6.3.2.Market Share Analysis, By Country
6.4. Home Care Settings
6.4.1.Market Size and Forecast, By RegionÂ
6.4.2.Market Share Analysis, By Country
CHAPTER 7: Â SMART INSULIN PENS MARKET, BY REGION
7.1.Market Overview
7.1.1Market Size and Forecast, By Region
7.2.North America
7.2.1.Key Market Trends and Opportunities
7.2.2.Market Size and Forecast, By Type
7.2.3.Market Size and Forecast, By Usability
7.2.4.Market Size and Forecast, By End User
7.2.5.Market Size and Forecast, By Country
7.2.6.United States Smart Insulin Pens Market
7.2.6.1.Market Size and Forecast, By Type
7.2.6.2.Market Size and Forecast, By Usability
7.2.6.3.Market Size and Forecast, By End User
7.2.7.Canada Smart Insulin Pens Market
7.2.7.1.Market Size and Forecast, By Type
7.2.7.2.Market Size and Forecast, By Usability
7.2.7.3.Market Size and Forecast, By End User
7.2.8.Mexico Smart Insulin Pens Market
7.2.8.1.Market Size and Forecast, By Type
7.2.8.2.Market Size and Forecast, By Usability
7.2.8.3.Market Size and Forecast, By End User
7.3.Europe
7.3.1.Key Market Trends and Opportunities
7.3.2.Market Size and Forecast, By Type
7.3.3.Market Size and Forecast, By Usability
7.3.4.Market Size and Forecast, By End User
7.3.5.Market Size and Forecast, By Country
7.3.6.Germany Smart Insulin Pens Market
7.3.6.1.Market Size and Forecast, By Type
7.3.6.2.Market Size and Forecast, By Usability
7.3.6.3.Market Size and Forecast, By End User
7.3.7.France Smart Insulin Pens Market
7.3.7.1.Market Size and Forecast, By Type
7.3.7.2.Market Size and Forecast, By Usability
7.3.7.3.Market Size and Forecast, By End User
7.3.8.Uk Smart Insulin Pens Market
7.3.8.1.Market Size and Forecast, By Type
7.3.8.2.Market Size and Forecast, By Usability
7.3.8.3.Market Size and Forecast, By End User
7.3.9.Italy Smart Insulin Pens Market
7.3.9.1.Market Size and Forecast, By Type
7.3.9.2.Market Size and Forecast, By Usability
7.3.9.3.Market Size and Forecast, By End User
7.3.10.Spain Smart Insulin Pens Market
7.3.10.1.Market Size and Forecast, By Type
7.3.10.2.Market Size and Forecast, By Usability
7.3.10.3.Market Size and Forecast, By End User
7.3.11.Rest Of Europe Smart Insulin Pens Market
7.3.11.1.Market Size and Forecast, By Type
7.3.11.2.Market Size and Forecast, By Usability
7.3.11.3.Market Size and Forecast, By End User
7.4.Asia-Pacific
7.4.1.Key Market Trends and Opportunities
7.4.2.Market Size and Forecast, By Type
7.4.3.Market Size and Forecast, By Usability
7.4.4.Market Size and Forecast, By End User
7.4.5.Market Size and Forecast, By Country
7.4.6.Japan Smart Insulin Pens Market
7.4.6.1.Market Size and Forecast, By Type
7.4.6.2.Market Size and Forecast, By Usability
7.4.6.3.Market Size and Forecast, By End User
7.4.7.China Smart Insulin Pens Market
7.4.7.1.Market Size and Forecast, By Type
7.4.7.2.Market Size and Forecast, By Usability
7.4.7.3.Market Size and Forecast, By End User
7.4.8.India Smart Insulin Pens Market
7.4.8.1.Market Size and Forecast, By Type
7.4.8.2.Market Size and Forecast, By Usability
7.4.8.3.Market Size and Forecast, By End User
7.4.9.Australia Smart Insulin Pens Market
7.4.9.1.Market Size and Forecast, By Type
7.4.9.2.Market Size and Forecast, By Usability
7.4.9.3.Market Size and Forecast, By End User
7.4.10.Rest Of Asia-pacific Smart Insulin Pens Market
7.4.10.1.Market Size and Forecast, By Type
7.4.10.2.Market Size and Forecast, By Usability
7.4.10.3.Market Size and Forecast, By End User
7.5.LAMEA
7.5.1.Key Market Trends and Opportunities
7.5.2.Market Size and Forecast, By Type
7.5.3.Market Size and Forecast, By Usability
7.5.4.Market Size and Forecast, By End User
7.5.5.Market Size and Forecast, By Country
7.5.6.Brazil Smart Insulin Pens Market
7.5.6.1.Market Size and Forecast, By Type
7.5.6.2.Market Size and Forecast, By Usability
7.5.6.3.Market Size and Forecast, By End User
7.5.7.Saudi Arabia Smart Insulin Pens Market
7.5.7.1.Market Size and Forecast, By Type
7.5.7.2.Market Size and Forecast, By Usability
7.5.7.3.Market Size and Forecast, By End User
7.5.8.South Africa Smart Insulin Pens Market
7.5.8.1.Market Size and Forecast, By Type
7.5.8.2.Market Size and Forecast, By Usability
7.5.8.3.Market Size and Forecast, By End User
7.5.9.Rest of LAMEA Smart Insulin Pens Market
7.5.9.1.Market Size and Forecast, By Type
7.5.9.2.Market Size and Forecast, By Usability
7.5.9.3.Market Size and Forecast, By End User
CHAPTER 8: Â COMPANY PROFILES
8.1. Berlin-Chemie
8.1.1.Company Overview
8.1.2.Key Executives
8.1.3.Company snapshot
8.1.4.Operating business segments
8.1.5.Product portfolio
8.1.6.Business Performance
8.1.7.Key Strategic Moves and Developments
8.2. Bigfoot Biomedical
8.2.1.Company Overview
8.2.2.Key Executives
8.2.3.Company snapshot
8.2.4.Operating business segments
8.2.5.Product portfolio
8.2.6.Business Performance
8.2.7.Key Strategic Moves and Developments
8.3. Digital Medics Pty Ltd.
8.3.1.Company Overview
8.3.2.Key Executives
8.3.3.Company snapshot
8.3.4.Operating business segments
8.3.5.Product portfolio
8.3.6.Business Performance
8.3.7.Key Strategic Moves and Developments
8.4. Eli Lilly And Company
8.4.1.Company Overview
8.4.2.Key Executives
8.4.3.Company snapshot
8.4.4.Operating business segments
8.4.5.Product portfolio
8.4.6.Business Performance
8.4.7.Key Strategic Moves and Developments
8.5. Emperra GmbH
8.5.1.Company Overview
8.5.2.Key Executives
8.5.3.Company snapshot
8.5.4.Operating business segments
8.5.5.Product portfolio
8.5.6.Business Performance
8.5.7.Key Strategic Moves and Developments
8.6. Jiangsu Deflu Medical Device Co. Ltd.
8.6.1.Company Overview
8.6.2.Key Executives
8.6.3.Company snapshot
8.6.4.Operating business segments
8.6.5.Product portfolio
8.6.6.Business Performance
8.6.7.Key Strategic Moves and Developments
8.7. Medtronic PLC
8.7.1.Company Overview
8.7.2.Key Executives
8.7.3.Company snapshot
8.7.4.Operating business segments
8.7.5.Product portfolio
8.7.6.Business Performance
8.7.7.Key Strategic Moves and Developments
8.8. Novo Nordisk
8.8.1.Company Overview
8.8.2.Key Executives
8.8.3.Company snapshot
8.8.4.Operating business segments
8.8.5.Product portfolio
8.8.6.Business Performance
8.8.7.Key Strategic Moves and Developments
8.9. Pendiq
8.9.1.Company Overview
8.9.2.Key Executives
8.9.3.Company snapshot
8.9.4.Operating business segments
8.9.5.Product portfolio
8.9.6.Business Performance
8.9.7.Key Strategic Moves and Developments
8.10. Sanofi
8.10.1.Company Overview
8.10.2.Key Executives
8.10.3.Company snapshot
8.10.4.Operating business segments
8.10.5.Product portfolio
8.10.6.Business Performance
8.10.7.Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1.GLOBAL SMART INSULIN PENS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 2.GLOBAL SMART INSULIN PENS MARKET FOR FIRST GENERATION PENS, BY REGION, 2020-2030 ($MILLION)
TABLE 3.GLOBAL SMART INSULIN PENS MARKET FOR SECOND GENERATION PENS, BY REGION, 2020-2030 ($MILLION)
TABLE 4.GLOBAL SMART INSULIN PENS MARKET, BY USABILITY, 2020-2030 ($MILLION)
TABLE 5.GLOBAL SMART INSULIN PENS MARKET FOR PREFILLED, BY REGION, 2020-2030 ($MILLION)
TABLE 6.GLOBAL SMART INSULIN PENS MARKET FOR REUSABLE, BY REGION, 2020-2030 ($MILLION)
TABLE 7.GLOBAL SMART INSULIN PENS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 8.GLOBAL SMART INSULIN PENS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2020-2030 ($MILLION)
TABLE 9.GLOBAL SMART INSULIN PENS MARKET FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2020-2030 ($MILLION)
TABLE 10.GLOBAL SMART INSULIN PENS MARKET FOR HOME CARE SETTINGS, BY REGION, 2020-2030 ($MILLION)
TABLE 11.GLOBAL SMART INSULIN PENS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 12.NORTH AMERICA SMART INSULIN PENS, BY Region, 2020-2030 ($MILLION)
TABLE 13.NORTH AMERICA SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 14.NORTH AMERICA SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 15.NORTH AMERICA SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 16.UNITED STATES SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 17.UNITED STATES SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 18.UNITED STATES SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 19.CANADA SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 20.CANADA SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 21.CANADA SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 22.MEXICO SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 23.MEXICO SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 24.MEXICO SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 25.EUROPE SMART INSULIN PENS, BY Region, 2020-2030 ($MILLION)
TABLE 26.EUROPE SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 27.EUROPE SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 28.EUROPE SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 29.GERMANY SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 30.GERMANY SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 31.GERMANY SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 32.FRANCE SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 33.FRANCE SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 34.FRANCE SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 35.UK SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 36.UK SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 37.UK SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 38.ITALY SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 39.ITALY SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 40.ITALY SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 41.SPAIN SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 42.SPAIN SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 43.SPAIN SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 44.REST OF EUROPE SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 45.REST OF EUROPE SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 46.REST OF EUROPE SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 47.ASIA-PACIFIC SMART INSULIN PENS, BY Region, 2020-2030 ($MILLION)
TABLE 48.ASIA-PACIFIC SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 49.ASIA-PACIFIC SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 50.ASIA-PACIFIC SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 51.JAPAN SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 52.JAPAN SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 53.JAPAN SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 54.CHINA SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 55.CHINA SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 56.CHINA SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 57.INDIA SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 58.INDIA SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 59.INDIA SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 60.AUSTRALIA SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 61.AUSTRALIA SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 62.AUSTRALIA SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 63.REST OF ASIA-PACIFIC SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 64.REST OF ASIA-PACIFIC SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 65.REST OF ASIA-PACIFIC SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 66.LAMEA SMART INSULIN PENS, BY Region, 2020-2030 ($MILLION)
TABLE 67.LAMEA SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 68.LAMEA SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 69.LAMEA SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 70.BRAZIL SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 71.BRAZIL SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 72.BRAZIL SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 73.SAUDI ARABIA SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 74.SAUDI ARABIA SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 75.SAUDI ARABIA SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 76.SOUTH AFRICA SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 77.SOUTH AFRICA SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 78.SOUTH AFRICA SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 79.REST OF LAMEA SMART INSULIN PENS, BY TYPE, 2020-2030 ($MILLION)
TABLE 80.REST OF LAMEA SMART INSULIN PENS, BY USABILITY, 2020-2030 ($MILLION)
TABLE 81.REST OF LAMEA SMART INSULIN PENS, BY END USER, 2020-2030 ($MILLION)
TABLE 82.BERLIN-CHEMIE: KEY EXECUTIVES
TABLE 83.BERLIN-CHEMIE: COMPANY SNAPSHOT
TABLE 84.BERLIN-CHEMIE: OPERATING SEGMENTS
TABLE 85.BERLIN-CHEMIE: PRODUCT PORTFOLIO
TABLE 86.BERLIN-CHEMIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 87.BIGFOOT BIOMEDICAL: KEY EXECUTIVES
TABLE 88.BIGFOOT BIOMEDICAL: COMPANY SNAPSHOT
TABLE 89.BIGFOOT BIOMEDICAL: OPERATING SEGMENTS
TABLE 90.BIGFOOT BIOMEDICAL: PRODUCT PORTFOLIO
TABLE 91.BIGFOOT BIOMEDICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 92.DIGITAL MEDICS PTY LTD.: KEY EXECUTIVES
TABLE 93.DIGITAL MEDICS PTY LTD.: COMPANY SNAPSHOT
TABLE 94.DIGITAL MEDICS PTY LTD.: OPERATING SEGMENTS
TABLE 95.DIGITAL MEDICS PTY LTD.: PRODUCT PORTFOLIO
TABLE 96.DIGITAL MEDICS PTY LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97.ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 98.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 99.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 100.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 101.ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 102.EMPERRA GMBH: KEY EXECUTIVES
TABLE 103.EMPERRA GMBH: COMPANY SNAPSHOT
TABLE 104.EMPERRA GMBH: OPERATING SEGMENTS
TABLE 105.EMPERRA GMBH: PRODUCT PORTFOLIO
TABLE 106.EMPERRA GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 107.JIANGSU DEFLU MEDICAL DEVICE CO. LTD.: KEY EXECUTIVES
TABLE 108.JIANGSU DEFLU MEDICAL DEVICE CO. LTD.: COMPANY SNAPSHOT
TABLE 109.JIANGSU DEFLU MEDICAL DEVICE CO. LTD.: OPERATING SEGMENTS
TABLE 110.JIANGSU DEFLU MEDICAL DEVICE CO. LTD.: PRODUCT PORTFOLIO
TABLE 111.JIANGSU DEFLU MEDICAL DEVICE CO. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 112.MEDTRONIC PLC: KEY EXECUTIVES
TABLE 113.MEDTRONIC PLC: COMPANY SNAPSHOT
TABLE 114.MEDTRONIC PLC: OPERATING SEGMENTS
TABLE 115.MEDTRONIC PLC: PRODUCT PORTFOLIO
TABLE 116.MEDTRONIC PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 117.NOVO NORDISK: KEY EXECUTIVES
TABLE 118.NOVO NORDISK: COMPANY SNAPSHOT
TABLE 119.NOVO NORDISK: OPERATING SEGMENTS
TABLE 120.NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 121.NOVO NORDISK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 122.PENDIQ: KEY EXECUTIVES
TABLE 123.PENDIQ: COMPANY SNAPSHOT
TABLE 124.PENDIQ: OPERATING SEGMENTS
TABLE 125.PENDIQ: PRODUCT PORTFOLIO
TABLE 126.PENDIQ: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 127.SANOFI: KEY EXECUTIVES
TABLE 128.SANOFI: COMPANY SNAPSHOT
TABLE 129.SANOFI: OPERATING SEGMENTS
TABLE 130.SANOFI: PRODUCT PORTFOLIO
TABLE 131.SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1.GLOBAL SMART INSULIN PENS MARKET SEGMENTATION
FIGURE 2.GLOBAL SMART INSULIN PENS MARKET
FIGURE 3.SEGMENTATION SMART INSULIN PENS MARKET
FIGURE 4.TOP INVESTMENT POCKET IN SMART INSULIN PENS MARKET
FIGURE 5.TOP WINNING STRATEGIES, 2019-2021*
FIGURE 6.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%)
FIGURE 7.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*
FIGURE 8.MODERATE BARGAINING POWER OF BUYERS
FIGURE 9.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
FIGURE 11.LOW THREAT OF SUBSTITUTION
FIGURE 12.HIGH COMPETITIVE RIVALRY
FIGURE 13.TOP PLAYER POSITIONING, 2020
FIGURE 14.MARKET SHARE ANALYSIS, 2020
FIGURE 15.RESTRAINTS AND DRIVERS: SMART INSULIN PENS MARKET
FIGURE 16.SMART INSULIN PENS MARKET SEGMENTATION, BY TYPE
FIGURE 17.SMART INSULIN PENS MARKET FOR FIRST GENERATION PENS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 18.SMART INSULIN PENS MARKET FOR SECOND GENERATION PENS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 19.SMART INSULIN PENS MARKET SEGMENTATION, BY USABILITY
FIGURE 20.SMART INSULIN PENS MARKET FOR PREFILLED, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 21.SMART INSULIN PENS MARKET FOR REUSABLE, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 22.SMART INSULIN PENS MARKET SEGMENTATION, BY END USER
FIGURE 23.SMART INSULIN PENS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 24.SMART INSULIN PENS MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 25.SMART INSULIN PENS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 26.BERLIN-CHEMIE: NET SALES, 2018-2020 ($MILLION)
FIGURE 27.BERLIN-CHEMIE: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 28.BERLIN-CHEMIE: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 29.BIGFOOT BIOMEDICAL: NET SALES, 2018-2020 ($MILLION)
FIGURE 30.BIGFOOT BIOMEDICAL: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 31.BIGFOOT BIOMEDICAL: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 32.DIGITAL MEDICS PTY LTD.: NET SALES, 2018-2020 ($MILLION)
FIGURE 33.DIGITAL MEDICS PTY LTD.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 34.DIGITAL MEDICS PTY LTD.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 35.ELI LILLY AND COMPANY: NET SALES, 2018-2020 ($MILLION)
FIGURE 36.ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 37.ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 38.EMPERRA GMBH: NET SALES, 2018-2020 ($MILLION)
FIGURE 39.EMPERRA GMBH: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 40.EMPERRA GMBH: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 41.JIANGSU DEFLU MEDICAL DEVICE CO. LTD.: NET SALES, 2018-2020 ($MILLION)
FIGURE 42.JIANGSU DEFLU MEDICAL DEVICE CO. LTD.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 43.JIANGSU DEFLU MEDICAL DEVICE CO. LTD.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 44.MEDTRONIC PLC: NET SALES, 2018-2020 ($MILLION)
FIGURE 45.MEDTRONIC PLC: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 46.MEDTRONIC PLC: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 47.NOVO NORDISK: NET SALES, 2018-2020 ($MILLION)
FIGURE 48.NOVO NORDISK: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 49.NOVO NORDISK: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 50.PENDIQ: NET SALES, 2018-2020 ($MILLION)
FIGURE 51.PENDIQ: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 52.PENDIQ: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 53.SANOFI: NET SALES, 2018-2020 ($MILLION)
FIGURE 54.SANOFI: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 55.SANOFI: REVENUE SHARE, BY REGION, 2020 (%)
According to the analyst perspectives, the adoption of needle free injection system is expected to increase in near future due to surge in the incidence of diabetics, low cost of insulin pens as compared to insulin pumps, and less injection pain caused than syringes. In addition, benefit of smart insulin pens is that it can be easily used by people with visual or motor skills impairments, which further fuels the market growth. However, dearth of trained personnel and limitation in usage for intravenous administration are expected to hamper the market growth. As per the analyst perspectives, the use of these devices is the highest in Europe, owing to heavy expenditure by the government on healthcare. It is followed by North America and Asia-Pacific, respectively.
A. The total market value of smart insulin pens market is $298.9 million in 2030.
A. The market value of smart insulin pens market in 2020 is $94.8 million.
A. The advancements in R&D activities in the healthcare sector, increase in diabetic population, advancements in the smart insulin pens products and the launch of new products are the key trends in the smart insulin pens market report.
A. Yes, the smart insulin pens market companies are profiled in the report.
A. Yes, the smart insulin pens market report provides PORTER Analysis
Start reading instantly.
This Report and over 66,905+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report